Abstract
Niraparib efficacy, safety, and QOL were similar in compared age groups. Implementation of an ISD regimen improved rates of grade ≥3 thrombocytopenia events in older patients.
- Title
- Efficacy and safety of niraparib in older patients with advanced ovarian cancer (OC): results from the PRIMA/ENGOT-OV26/GOG-3012 trial
- Creators
- F HeitzG ValabregaB PothuriA OakninW GraybillA. B SanchezC McCormickJ. F BaurainP HoskinsH DenysR. E O'CearbhaillS HietanenR. G MooreA. O Knudsende La Motte T RougeT LevyY LiD GuptaB. J MonkA Gonzalez-Martin
- Identifiers
- 991005969034502656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Conference proceeding